References
- Demoly P, Castells M. Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium. World Allergy Organ J. 2018;11(1):42. doi:10.1186/s40413-018-0224-130598723
- Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg. 2019;74(4):272–279. doi:10.1080/17843286.2018.152190430253707
- Mohammed R, Milne A, Kayani K, Ojha U. How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas. J Blood Med. 2019;10:71–84. doi:10.2147/JBM.S19078430881167
- Wong JT, Long A. Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms. J Allergy Clin Immunol Pract. 2017;5(6):1564–1571. doi:10.1016/j.jaip.2017.08.00429122155
- Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy. 2014;69(4):420–437. doi:10.1111/all.1235024697291
- Tsao LR, Young FD, Otani IM, Castells MC. Hypersensitivity reactions to platinum agents and taxanes. Clin Rev Allergy Immunol. 2021. doi:10.1007/s12016-021-08877-y
- Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(2):177–191. doi:10.1007/s12016-014-8416-024740483
- Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109–1117. doi:10.1056/NEJMoa07494318337601
- Vultaggio A, Matucci A, Nencini F, et al. Mechanisms of drug desensitization: not only mast cells. Front Pharmacol. 2020;11:590991. doi:10.3389/fphar.2020.59099133424601
- Kepil Ozdemir S, Gorgulu B, Doganay Erdogan B, et al. Effect of drug desensitization on drug hypersensitivity-related quality of life. J Allergy Clin Immunol Pract. 2020;9(4):1738–1741.e1. doi:10.1016/j.jaip.2020.10.05533186768
- Broyles AD, Banerji A, Barmettler S, et al. Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs. J Allergy Clin Immunol Pract. 2020;8(9S):S16–S116. doi:10.1016/j.jaip.2020.08.00633039007
- Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371–376. doi:10.1016/j.jaci.2004.04.02915316518
- Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–1266. doi:10.1016/j.jaci.2009.09.00919910036
- Fouda GE, Bavbek S. Rituximab hypersensitivity: from clinical presentation to management. Front Pharmacol. 2020;11:572863. doi:10.3389/fphar.2020.57286333013416
- Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, et al. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):159–170 e152. doi:10.1016/j.jaci.2018.02.01829518427
- Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46(7):907–922. doi:10.1111/cea.1276027196817
- Stone CA Jr., Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533–1540 e1538. doi:10.1016/j.jaip.2018.12.00330557713